



CSD/BSE&NSE/2024-25
August 05, 2024

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Statement of Deviation(s) or variation(s) for quarter ended 30th June, 2024 under Regulation 32 of SEBI (LODR) Regulations, 2015

.....

With reference to the above subject, please find enclosed statement confirming that there were **no deviation(s) or variation(s) in the use of proceeds**, from the objects for which funds were raised through the Rights Issue made by the Company, for the quarter ended 30th June, 2024.

We request you to take this on your record.

Thanking you.



Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Company Secretary
M. No.: F12400
Encl.: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Email: info@suven.com website: www.suven.com

| Statement of Deviation / Variation in utilisation of funds raised | | | | | | |
|---|------------------------------------|--------------------------------|-----------------------------|---------------------------|---|--|
| Name of listed entity | Suven Life Sciences Limited | | | | | |
| Mode of Fund Raising | Rights Issue | | | | | |
| Date of Raising Funds (Allotment) | 16/11/2022 | | | | | |
| Total Amount Raised (in Rs. crores) | Rs. 399.80 Crores. | | | | | |
| Report filed for Quarter ended | 30 June, 2024 | | | | | |
| Monitoring Agency | Applicable | | | | | |
| Monitoring Agency Name, if applicable | CRISIL Ratings Limited | | | | | |
| Is there a Deviation / Variation in use of funds raised | No | | | | | |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | Not Applicable | | | | | |
| If Yes, Date of shareholder Approval | Not Applicable | | | | | |
| Explanation for the Deviation / Variation | Not Applicable | | | | | |
| Comments of the Audit Committee after review | Nil | | | | | |
| Comments of the auditors, if any | Not Applicable | | | | | |
| Objects for which funds have been raised and where there has been a deviation, in the following table | As mentioned below. | | | | | |
| Original Object | Modified Object, if any | Original Allocation (A) | Modified allocation, if any | Funds Utilized (B) | Amount of Deviation/ Variation for the quarter according to applicable object | Remarks if any |
| Meeting costs related to pharmaceutical research and development and clinical trial for molecules in the research pipelines | Not Applicable | Rs. 250.01 Crore | Not Applicable | Rs. 205.26 Crore | Not Applicable | The difference amount (A-B) of Rs. 44.75 Crore is yet to be utilized as on 30/06/2024. |

| | | | | | | |
|---|----------------|-----------------|----------------|-----------------|----------------|--|
| Repayment of Inter-corporate deposit availed by Company | Not Applicable | Rs. 50.00 Crore | Not Applicable | 50.00 Crore | Not Applicable | The allocated amount was fully utilized towards the said object during the quarter ended 31/12/2022. |
| General corporate purpose | Not Applicable | Rs. 96.99 Crore | Not Applicable | Rs. 31.60 Crore | Not Applicable | The difference amount (A-B) of Rs. 65.39 Crore is yet to be utilized as on 30/06/2024. |
| <i>Deviation or variation could mean:</i> | | | | | | |
| <i>(a) Deviation in the objects or purposes for which the funds have been raised or</i> | | | | | | |
| <i>(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or</i> | | | | | | |
| <i>(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc</i> | | | | | | |
| For Suven Life Sciences Limited  M. Mohan Kumar Chief Financial Officer  | | | | | | |